The drastic cost-cutting move followa the deaths of two teenagers that forced the company to restrict usage of its gene ...

The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.

New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular ...

Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the ...

Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta ...

Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the recent deaths of two patients ...

The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment ...

Sarepta Therapeutics faces a challenging period as it navigates recent setbacks with its groundbreaking gene therapy, leading ...

Shares of struggling drug developer Sarepta Therapeutics skyrocketed nearly 40% in extended trading Wednesday after the company unveiled a major restructuring plan.

Norwegian documentary, The Remarkable Life of Ibelin, directed by Benjamin Ree, chronicles the life of Mats Steen, who had ...

Dysfunctional dystrophin, the muscle protein affected in Duchenne, leads to an important choice for patients about how to approach physical activity and exercise. While physical activity may help ...